Stocksigma LogoStocksigma Logo

Mankind Pharma Acquires 70% Stake in Armed Cell Therapeutics for EUR 48Mn

Mankind Pharma approved an additional investment of up to EUR 45Mn into wholly owned subsidiary Mankind Pharma (Netherlands) B.V

Mankind Pharma Acquires 70% Stake in Armed Cell Therapeutics for EUR 48Mn

Mankind Pharma Ltd 路 Others (Uncategorized) 路 16 Oct 2026, 12:57 am

Mankind Pharma Acquires 70% Stake in Armed Cell Therapeutics for EUR 48Mn Mankind Pharma approved an additional investment of up to EUR 45Mn into wholly owned subsidiary Mankind Pharma (Netherlands) B.V. on 15th Oct'26, raising its total investment limit to EUR 50Mn. The subsidiary will utilize EUR 48Mn in cash instalments to acquire a 70% majority stake in Belgium-based Armed Cell Therapeutics B.V. (ACTx). ACTx specializes in next-generation CAR-T cancer therapies, focusing on non-Hodgkin lymphoma and small cell lung cancer. The transaction marks Mankind's strategic expansion into global, innovation-led oncology biopharmaceuticals.

Original exchange filing (PDF)

More announcements from Mankind Pharma Ltd

All Mankind Pharma Ltd announcements